期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期非鳞非小细胞肺癌一线诱导化疗后贝伐单抗联合培美曲塞维持治疗的疗效和安全性 被引量：5

Efficacy and Safety of Maintenance Bevacizumab Combined with Pemetrexed after First-Line Induction Chemotherapy in Advanced Nonsquamous Non-Small Cell Lung Cancer
下载PDF
导出
摘要 1文献来源 Bartesi F, Scherpereel A, Rittmeyer A, et al.Randomized phase m trial of maintenance Bevacizumab with or without Pemetrexed after firstline induction with Bevacizumab, Cisplatin, and Pemetrexed in advanced nonsquamous non-small-cell lung cancer： AVAPERL （MO22089）[J]. J Clin Oncol, 2013,2013,31 （24） ： 3004-3011.
作者 刘晓晴 李锋
机构地区 解放军第 广东省人民医院肿瘤中心
出处 《循证医学》 CSCD 2014年第1期33-36,40,共5页 The Journal of Evidence-Based Medicine
关键词 非小细胞肺癌 培美曲塞 贝伐单抗 维持治疗 non-small cell Lung cancer Pemetrexed Bevacizumab maintenance therapy
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献4

  • 1Paz-Ares L,de Marinis F,Dediu M. Maintenance therapy with Pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with Pemetrexed plus Cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT):A double-blind,phase 3,randomized controlled trial[J].The Lancet Oncology,2012,(03):247-255.
  • 2Sandler A,Gray R,Perry MC. Paclitaxel-Carboplatin alone or with Bevacizumab for non-small-cell lung cancer[J].New England Journal of Medicine,2006,(24):2542-2550.
  • 3Ciuleanu T,Brodowicz T,Zielinski C. Maintenance Pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer:A randomised,double-blind,phase 3 study[J].The Lancet,2009,(9699):1432-1440.
  • 4Patel JD,Socinski MA,Garon EB. Point Break:A randomized phase Ⅲ study of Pemetrexed plus Carboplatin and Bevacizumab followed by maintenance Pemetrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab followed by maintenance Bevacizumab in patients with stage Ⅲ B or Ⅳ nonsquamous non-small-cell lung cancer[J].Journal of Clinical Oncology,2013,(34):4349-4357.

同被引文献39

  • 1周立霞,哈敏文.贝伐单抗联合培美曲塞加卡铂二线治疗晚期非小细胞肺癌的临床观察[J].中国药房,2011,22(6):529-531. 被引量：11
  • 2张妮,曾维威,张献全.培美曲塞维持治疗晚期非小细胞肺癌的Meta分析[J].中国老年学杂志,2014,34(7):1774-1776. 被引量：4
  • 3裘雁冰,陆益,吴洪斌,凌云华.贝伐单抗及其联用化疗方案的不良反应[J].药物不良反应杂志,2006,8(6):431-433. 被引量：27
  • 4王晓红,刘永刚,盂知颖,等.贝伐单抗联合培美曲塞一线治疗晚期非小细胞肺癌的临床观察[J].CSCO学术年会论文汇编,2012:142-143.
  • 5瞿潇.维持治疗对晚期非小细胞肺癌临床疗效的系统评价[D].山东大学2014
  • 6Ebisawa Y, Chisato N, Okayama T, et al. Long-term survivalof a patient with advanced colon cancer and para-aortic lymphnode metastases treated with re-administration of high-dosemolecular targeted agent bevacizumab [J] . Gan To KagakuRyoho,2013,40(10):1401-1404.
  • 7Tokarski S, Rutkowski M, Godala M, et al. The impact ofascorbic acid on the concentrations of antioxidative vitaminsin the plasma of patients with non-small cell lung cancerundergoing first-line chemotherapy [J] . Pol Merkur Lekarski,2013,35(27):136-140.
  • 8Chan BA, Coward JI. Chemotherapy advances in small-celllung cancer [J] . J Thorac Dis, 2013, 5 Suppl 5: S565-578.DOI: 10. 3978/j. issn. 2072-1439. 2013. 07. 43.
  • 9Zaric B, Stojsic V,Tepavac A, et al. Adjuvant chemotherapyand radiotherapy in the treatment of non-small cell lungcancer (NSCLC) [J] . J Thorac Dis, 2013, 5 ( Suppl 4) : S371-377. DOI: 10. 3978/j. issn. 2072-1439. 2013. 05.16.
  • 10Bergot E, Levallet G,Campbell K, et al. Predictive biomarkersin patients with resected non-small cell lung cancer treatedwith perioperative chemotherapy [J] . Eur Respir Rev, 2013,22(130) :565-576. DOI: 10.1183/09059180.00007113.

引证文献5

二级引证文献12

循证医学
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部